In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Improvement in ejection fraction predicts heart failure after catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction : from the KPAF registry

Session Poster Session 6

Speaker Hajime Fujimoto

Congress : ESC Congress 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Rhythm Control, Catheter Ablation
  • Session type : Poster Session
  • FP Number : P5650

Authors : H Fujimoto (Nara,JP), N Doi (Nara,JP), K Hirai (Nara,JP), M Naito (Osaka,JP), S Shizuta (Kyoto,JP), A Kobori (Kobe,JP), K Inoue (Osaka,JP), K Kaitani (Otsu,JP), T Kurotobi (Osaka,JP), I Morishima (Ogaki,JP), K Satomi (Osaka,JP), H Yamaji (Okayama,JP), Y Nakazawa (Shiga,JP), K Kusano (Osaka,JP), T Kimura (Kyoto,JP)

H Fujimoto1 , N Doi1 , K Hirai2 , M Naito3 , S Shizuta4 , A Kobori5 , K Inoue6 , K Kaitani7 , T Kurotobi8 , I Morishima9 , K Satomi10 , H Yamaji11 , Y Nakazawa12 , K Kusano10 , T Kimura4 , 1Nara Prefectural Seiwa Medical Center - Nara - Japan , 2Nara Medical University, Cardiovascular medicine - Nara - Japan , 3Naito hospital, Internal medicine - Osaka - Japan , 4Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine - Kyoto - Japan , 5Kobe City Medical Center General Hospital, Division of Cardiology - Kobe - Japan , 6Sakurabashi-Watanabe Hospital, Cardiovascular center - Osaka - Japan , 7Japanese Red Cross Otsu Hospital, Cardiovascular medicine - Otsu - Japan , 8Shiroyama Hospital, Cardiovascular center - Osaka - Japan , 9Ogaki Municipal Hospital, Department of Cardiology - Ogaki - Japan , 10National Cerebral and Cardiovascular Center, Division of of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine - Osaka - Japan , 11Okayama Heart Clinic, Cardiovascular medicine - Okayama - Japan , 12Shiga University of Medical Science, Department of Cardiovascular Medicine, Heart Rhythm Center - Shiga - Japan ,


Introduction: The presence of atrial fibrillation (AF) in patients with reduced left ventricular ejection fraction (LVEF) is associated with increased risks of mortality and hospitalization for heart failure (HF). Although prior studies reported that catheter ablation (CA) for AF in low LVEF patients reduced risks of all-cause mortality and HF hospitalization, the predictors of worsening HF after ablation has not been adequately evaluated.
Purpose: The purpose of this study was to investigate the impact of improvement in LVEF after AF ablation on the incidence of subsequent HF hospitalization in patients with low LVEF.
Methods: The Kansai Plus Atrial Fibrillation (KPAF) Registry is a multicenter registry enrolling 5,013 consecutive patients undergoing first-time ablation for AF. The current study population consisted of 1,031 patients with reduced LVEF of <60%. We divided the study population into 3 groups according to LVEF at follow-up; 678 patients (65.8%) with improved LVEF (= 5 U change in LVEF), 288 patients (27.9%) with unchanged LVEF (-5 U = change in LVEF < 5 U) and 65 patients (6.3%) with worsened LVEF (< -5 U change in LVEF).
Results: During the median follow-up of 1067 [879-1226] days, patients improved LVEF had lower rate of HF hospitalization, compared with those with unchanged and worsened LVEF (2.1%, 8.0%, and 21.5%, respectively, P<0.0001). Recurrent atrial tachyarrhythmias were documented in 43.5%, 47.2% and 67.7%, respectively (P=0.0008).
Conclusion: Among patients with reduced LVEF undergoing AF ablation, patients with subsequently improved LVEF in association with maintained sinus rhythm had markedly lower risk of HF hospitalization during follow-up as compared with those with unchanged or worsened LVEF.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are